未知生产厂商
Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.
Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.
Fontolizumab is a humanised antibody directed against recombinant human IFN-{gamma}. The antibody binds to natural human IFN-{gamma} and inhibits expression of IFN-{gamma} regulated genes known to be upregulated in Crohn’s disease.
Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
